• Metadoro
  • Products
  • News and analysis

News and analysis

Check market insights shared by our community members
20.01.2025
Investment Banks Are Ahead of Lenders

An advance guard of the U.S. banking segment has reported for the ending quarter of 2024 ahead of the corporate earnings season's major chapters, which are still coming in and are supposed to make an overall positive contribution. But what's interesting is, the variety of lending institutions performed a solid organic growth in terms of both revenue and pure income, while the essentially investment giants like Goldman Sachs (GS) and BlackRock (BLK) grew up on a much firmer foundation. There is an impression that well-organised asset management, based on proper contextual ad hoc and mid-term stock transactions, is still producing enhanced results when compared to the returns of somewhat shabby loan portfolios at still quite heavy interest rates.

A temporary increase in Blackrock market value was up to 6.5% at its highest intraday point on January 15, following its record ever $11.93 of equity per share (EPS) on an also absolutely highest number of $5.68 billion in quarterly sales. Blackrock's three-month achievements provided a 23.5% annual boost in EPS vs nearly14% expected at EPS of $11.06 per share, which was supposed in analyst pool projections in reputable news outlets like Bloomberg and Reuters. Many investment houses quickly adjusted their price target areas for Blackrock shares, while also keeping Outperform ratings on the stock. As an example, Keefe, Bruyette & Woods (KBW) revised its price goal for Blackrock to $1,180, citing the investment bank's diversified inflows and global expansion growth initiatives which made the company favorably positioning in the eyes of analysts and investors alike. Blackrock is currently traded around $1000 per share.

However, the Goldman Sachs (GS) effect even surpassed the previous case, with an emergence of totally new peaks above $625 on GS charts, where the shares of this widely recognized investment giant had never been before. The weekly gain was more than 11.5% from $560 per share at the closing price on January 10. Goldman Sachs provided last quarter's EPS at $11.95 per share, beating a $8.12 consensus forecast, with its revenue achieving as high as $13.87 billion vs $12.15 billion previously estimated on average. This means that GS net revenues are up 7% YoY but its adjusted income soared by 54%, so that the firm maintains its clear leadership in global investment banking, including merge and acquisition advisory and wealth management services. Such a strong kind of resilience revived inner projections for EPS of $47.50 for fiscal year 2025 and $52.50 for fiscal year 2026. Isn't this a ready-made reason for targets above $650, or even $700 per share in the coming months, or at least before the end of 2025? By the way, Goldman Sachs CEO David Solomon was freshly rewarded by an $80 million stock bonus to stay at the helm for another 5 years, and John Waldron, a chief operating officer who is seen by many as a successor to Solomon, who is 63 now, was also awarded with his retention bonus of the same $80 million in restricted stock. However, the huge crowd of Goldman Sachs investors on Wall Street is hardly feeling offended or sad either, given the stock's crazy growth pace by the banking segment's standards.

The very fact that a cycle of lower borrowing rates has started in 2024 on both sides of the pond is helping the banking environment tremendously, which may in turn expand into a real business so soon, but the process may be happening more slowly than many Wall Street inhabitants would like to see due to a pause in the dovish shift by the Federal Reserve and other financial regulators. Wells Fargo (WFC), which also has an increasingly advanced investment focus among its recovering lending business, gained more than 8% since last week's earnings' report, coming very close to all-time peaks around $78 per share. Shares of JPMorgan Chase (JPM) and Morgan Stanley (MS) also broke their previous price records, but gained within 5% and 7%, while the Bank of America (BAC) failed to add more than 2% for the reporting week, while its quarterly profits and sales were high but still within its previous lofty standards. The smaller part of investment business versus the credit component for the last three banks mentioned above seems like a reasonable justification for this tendency.

16.01.2025
Delta Is Taking Off To Update Its Highs

Delta Air Lines stock rose markedly by low double digits in the first ten days of the new year. The U.S. carrier has served more than 200 million customers in 2024, when it was also recognized by J.D. Power, a leading American data analytics and consumer intelligence company, for being No. 1 in First/Business and Premium Economy Passenger Satisfaction. Travelers became more willing to spend extra money for swanky seats when meeting a high level of service. Delta is just positioning itself as the nation's premium airline. And what's more important, its Christmas quarter's earnings reportedly surpassed average analyst pool projections. Driven by stronger travel demand, smart financial management and capacity discipline, Delta business provided last three-months' profit of $1.85 per share vs $1.28 at the same period one year ago, compared to $1.75 in consensus estimates. On January 10, the airline industry leader put its future profit levels within a range between $0.70 and $1 per share in the current quarter through the end of March, while analyst expectations were focused on $0.77 cents, according to data compiled by LSEG. The starting months of each year always perform worse. It is clear that all carriers made losses in the Covid years of 2020-2022, but Delta profits only recovered into a range from $0.25 to $0.45 in the first quarter of 2023 and 2024, respectively, but Q1 profit numbers varied from $0.75 to $0.96 even in the three blessed years before the pandemic. Delta added that it is forecasting annual earnings in excess of $7.35 a share, which would be the highest in its 100-year history, based on its planned revenue growth of 7% to 9% in the March quarter from a year ago. The announcement could be compared to an adjusted profit of $6.16 a share in 2024. The company happily breaks through ticket prices' rising effects, almost undisturbed by a reduction in airline seats in the domestic market, which was peculiar for most carriers. Thus, new expectations created a fertile ground for setting new price records, even though price movements on Delta charts look most convincing among its other American rivals.

By the way, Citigroup analysts freshly updated their outlook on Delta Air Lines shares to raise their price target to $80 from the previous $77, vs the actual range around $65 per share where the stock just came after a reasonable market correction from last week's and all-time highs. Citigroup said it has included factors like higher revenue per available seat mile, projections of slightly lower fuel prices, increased taxation, a minor rise in share count, and the incorporation of fourth-quarter 2024 results into their financial model, which has projected Delta's profit at $7.49 per share in 2024 and $8.72 in 2025. Delta shares are Buy-rated at Citi, and we agree with their positive estimates in general, while keeping in mind even better price goals somewhere between $82.5 and $85.

14.01.2025
Tezos Is Seen Hodling above $1.200

Tezos (XTZ) has declined slightly by 0.2% this week, trading at $1.249, following Bitcoin’s (BTC) drop to $89,158, which triggered widespread altcoin sell-offs due to concerns of a potential further decline in BTC to $80,000. However, Bitcoin managed to hold above the critical support level at $89,000-$91,000, offering some relief to the broader crypto market.

Speculation about a shift in U.S. trade policy has provided additional support to crypto assets. Reports suggest the new U.S. administration may pursue a gradual increase in tariffs rather than an abrupt hike, which could help alleviate inflationary pressures and lead to a less aggressive monetary stance from the Federal Reserve.

This development is a positive signal for the cryptocurrency market and may help Tezos maintain its position above the key support level of $1.200.

14.01.2025
Merck Becomes Interesting to Be Added to a Portfolio

Merck & Co (MRK) stocks have shown signs of becoming a compelling buy opportunity. Over the past six months, the stock has been in a downtrend, declining 29.8% to $94.50 per share. However, since mid-November, MRK has demonstrated a reversal of momentum, rebounding by 10.0% to reach $104.87 on December 5. Following a brief pullback and consolidation period, the stock has retested the downtrend resistance and appears poised to continue its upward trajectory.

With prices currently positioned to target $110.00, this represents a potential 9-10% upside from the present levels. Setting a stop-loss at $93.50 aligns with a prudent risk management strategy, providing protection against further downside while allowing for upside potential. The recent consolidation phase further supports the case for a breakout, making this an attractive moment to consider initiating or adding to a position in MRK.

09.01.2025
VeChain Is Suffering on Rising Borrowing Costs

VeChain (VET) has fallen 12.7% this week, trading at $0.0445, underperforming the broader cryptocurrency market. Bitcoin (BTC), the leading cryptocurrency, has declined by 5.6% to $93,220, with bearish momentum building as it approaches key support at $89,000-$91,000. This decline is largely attributed to tightening monetary conditions in the United States, which continue to weigh on risk assets. Investor confidence is further shaken by significant net outflows from spot BTC-ETFs, which lost $583 million on Wednesday, marking the second-largest single-day outflow on record.

If BTC falls below the critical support level of $89,000-$91,000, VeChain is likely to extend its losses, with prices potentially declining another 10% to $0.0400. A sustained drop in BTC could push VET even lower, towards $0.0300. Conversely, a strong rebound in BTC prices to the $100,000 level could drive VET back up to $0.0500, representing a recovery of approximately 12% from current levels.

Johnson & Johnson Failed To Reverse the Downtrend

Johnson and Johnson (JNJ) was the first member of the health consumer staples club to report in the spring on Wall Street. As a large producer of essential hygiene products, personal care items and services, it could reap the benefits of its unique positioning on markets as most people are addictive in their nature to the same kind of skin health brands and baby medications. JNJ is also one of the world leaders in providing prescription and over-the-counter drugs, surgical equipment and orthopaedic implants, which are difficult to be replaced by anything else. Nevertheless, the stock lost 2.15% of their value on April 16. As a result, a smoothly descending channel on monthly charts since the beginning of 2023 still stands intact.

Nominally, the Q1 growth numbers were even better than expected, with EPS (equity per share) coming out at $2.71 vs $2.64 of consensus projections. Yet, there is almost no increase in profit in absolute terms over the past two years, which means the medtech giant is earning less if adjusted for inflation effects. Therefore, even though J&J performance in the segment of innovative medicine could be called impressive, as it contributed to 63.5% of the company's sales amounting to $13.56 billion against preliminary estimates of $13.47 billion, most large investment houses were not satisfied. Some of them just preferred to moderately cut their mid-term targets for the company's price, in the range of $5 to $10 per share to the current levels around $145, citing a lacklustre in forward guidance parameters for the rest of 2024, foreign exchange headwinds (a reason why international sales declined by 0.3% Y0Y) and other factors like a potential loss of exclusivity for Stelara drug brand, which was designed to treat psoriasis, related arthritis and ulcerative colitis.

Johnson & Johnson sees its adjusted operational EPS to range between $10.60 and $10.75 for 2024, with "Innovative Medicine sales growth is expected to be stronger in the first half of the year". Does it mean that the second part of 2024 would experience a slowdown? Again, the Vision Care business of the giant has narrowed due to "changes in distributor inventory". JNJ's CEOs commented on the strategic acquisition of Shockwave Medical and Ambrx to strengthen the company's cardiovascular and oncology portfolios, which could be important but still questionable from the point of view of future financial return. The session of questions and answers during the conference call also included the multiple myeloma franchises and litigation related to some patents, while the company's representatives affirmed confidence in their solid position. The company's future prospect looks rather optimistic, yet the share price dynamics based on mentioned challenges suggests that prematurely buying of JNJ stock at any levels well above the lows of April 2020 may be unreasonable, if only no fresh fundamental drivers appear.

3560
B
The Rally Will Remain Safe and Sound

I don't think the recent S&P 500 retracement to a 5,050-5,075 area is threatening the stock rally. This short correction began last Friday only because of the clear drawdown in the US banking segment. I expected the trash scenario for the flagship banking stocks when I sold off my last remaining stocks of JPMorgan (JPM) just a day before the bearish signs were included into its weaker forward guidance as an attachment to a regular and strong quarterly report. I am not going to repeat all of my arguments behind the situation. Anyway, when other sectors of the market are mostly stable or unmoved, the downward momentum by several leading banks define the overall bearish mood for the broad indexes. Meanwhile, the fundamentals of the rally, especially in the AI and e-commerce segments, still look as strong as it was a couple of weeks ago and in recent months as well. Therefore, I feel comfortable to invest some free cash into temporarily discounted chip producers like AMD, or into the GPT chats based giants, including Microsoft and Google. I have no doubts in a step-by-step recovery of AMD from its current $160 per share to above $200 once again to cover a nearly 30% discount from its peaking price, even though high bond yields behind a drop in banking stocks, Middle East developments to some extent, may bring the S&P 500 to 5,000 or even a little bit lower when going with the flow. All this temporary agenda is hardly to change the basic instincts of large investment houses that avoid money and want more shares in growing businesses.

4128
Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
Tezos May Lose another 20.0%

Texos (XTZ) experienced a 1.6% decline this week, falling to $0.980 and still below the uptrend support at $1.000. The token's value plummeted by 27.0% on April 12-13 to levels not seen since January, triggered by escalation in the Middle East conflict. Although geopolitical tensions have since eased, the market has only managed to recover less than half of its weekend losses.

Investors seem surprised by XTZ's unexpected breakthrough below the support level, and their attempts to push prices back up have been unsuccessful over the past three days. If they are unable to restore prices above $1.000 soon, there is a likelihood of a further dive by 20.0% to $0.800.

3828
Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
BNB is Recovering to $600 amid General Market Recovery

Binance Coin (BNB) has shown a strong recovery this week, adding 6.0% to reach $584.00. This rebound follows a significant drop of 17.9% to $490.00 on April 13, which occurred in the midst of heightened volatility in the crypto market due to geopolitical tensions surrounding a massive missile strike on Israel. This event triggered a sell-off across various cryptocurrencies, with Bitcoin (BTC) also plummeting by 10.0% to $60,180, its lowest level since March 5.

However, the situation in the Middle East began to ease, leading to an overall recovery in crypto assets. Additionally, positive news emerged from the Hong Kong Securities and Futures Commission (SFC), which approved spot BTC and ETH ETFs on Monday. This decision opened up the crypto market to investors from mainland China, contributing to renewed optimism.

Bitcoin rose by 5.0% to $66,750 following the news, with a target set at $70,000 per coin. Similarly, Binance Coin (BNB) has been experiencing a recovery from its low of $500.00, potentially aiming for the $600.00 mark. If momentum continues to build, prices may even surpass this level and move higher, particularly in the event of a breakthrough.

3944
183

Join our community

Share your professional and amateur observations, exchange experiences, anticipate developments

Category
All
Stocks
Crypto
Etf
Commodities
Indices
Currencies
Energies
Metals
Instruments
Author
All
Metadoro
Contributors